MDASI Malignant Pleural Mesothelioma Module

• Purpose: To assess the severity of symptoms related to malignant pleural mesothelioma and the impact of these symptoms on daily functioning
• Population: Patients with symptoms caused by malignant pleural mesothelioma and its treatment
• Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
• Method: Self-report or interview with research staff; paper-and-pencil or electronic data entry*
• Time required: Five minutes or less
• Scoring: Please see the MDASI User Guide
• Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91

*Electronic data capture offers several benefits:

• Allows symptom monitoring when the patient is away from the hospital
• Is convenient for patients, who can choose web access, personalized patient portals, or smartphones to access questionnaires
• Minimizes missing data, especially in longitudinal studies
• Provides accurate, real-time symptom data at expected time points
• Generates immediate feedback, potentially allowing caregivers to address severe symptoms more effectively

Click on a linked language to view a sample in PDF format. 

Don't see a language you need?  Contact us at symptomresearch@mdanderson.org.

In response to the US Food and Drug Administration's 2009 guidance for the pharmaceutical industry on the use of patient-reported outcomes measures in medical product development to support labeling claims, we have prepared a MDASI User Guide to document the development and psychometric properties of the MDASI and its modules. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.

Validation

Mendoza TR, Williams LA, Keating KN, et al. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). J Patient Rep Outcomes 3(1):34, 2019. 

Williams LA, Whisenant MS, Mendoza TR, et al. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res 27(12):3229-3241, 2018.

Williams L, Cleeland C, Bamidele O, Simon G. Generation of symptom burden patient-reported outcomes for patients with lung cancer [abstract]. International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer, Yokohama, Japan, Oct 15-18, 2017. J Thorac Oncol 12(11 Supplement 2): S2024, 11/2017; Abstract #P1.10-005.

Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.

Methodology

Cleeland CS, Keating KN, Cuffel B, et al. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma. Sci Rep, in press.